Revenue distribution by industry:

• Biopharmaceutical industry: approx. 75%
• Laboratory technology: approx. 25%

TOP 3 markets and their percentage shares:

• USA: approx. 35%
• Europe (excluding Germany): approx. 30%
• Germany: approx. 15%

Sartorius Aktiengesellschaft generates the majority of its revenue in the biopharmaceutical industry, which accounts for about three quarters of total revenue. This sector benefits from the increasing demand for biopharmaceutical solutions and technologies.

The USA is the largest individual market for Sartorius, followed by Europe (excluding Germany) and Germany itself. These markets are crucial for the company as they have a high concentration of biopharmaceutical companies and research institutions that benefit from Sartorius' products and services.

Production sites of Sartorius Aktiengesellschaft:

1. Göttingen, Germany
2. Aubagne, France
3. Beijing, China
4. Yauco, Puerto Rico
5. Tucson, USA

Sartorius Aktiengesellschaft is a globally active company specializing in the manufacturing of laboratory and process technology. The main production sites are located in Germany, France, China, Puerto Rico, and the USA. These strategically distributed sites enable the company to efficiently respond to global market demands and optimize supply chains.

Revenue Growth: Expected to be 8-10% annually (2025-2027, estimate)
Investment Volume: Over 400 million euros annually (2025, estimate)

Sartorius Aktiengesellschaft is pursuing a growth strategy based on several pillars. Firstly, the company is focusing on continuously expanding its production capacities to meet the increasing demand in the biopharma industry. This includes significant investments in new production facilities and the modernization of existing plants.

Secondly, Sartorius is concentrating on strategic acquisitions to expand its product portfolio and integrate new technologies. These acquisitions aim to strengthen the market position in key regions and improve access to innovative solutions.

Furthermore, Sartorius is heavily investing in research and development to offer innovative products and services that meet the changing needs of customers. The focus is on digitizing and automating laboratory processes to increase efficiency and quality.

In summary, Sartorius aims for sustainable growth through capacity expansions, strategic acquisitions, and technological innovations to further strengthen its leading position in the biopharma sector.

Main raw materials: Cell culture media, filter membranes, plastic resins
Countries of origin: USA, China, Germany

Sartorius Aktiengesellschaft is a leading company in the biotechnology industry specializing in the manufacturing of laboratory and process technology. Among the main raw materials imported by Sartorius are cell culture media, filter membranes, and various plastic resins that are essential for the production of laboratory and bioprocess products.

The USA and China are significant suppliers of these materials, especially for cell culture media and plastic resins. Germany also plays an important role, particularly in the procurement of specialized filter membranes and other high-tech components. These raw materials are crucial for the production of Sartorius' high-precision products used in biopharmaceutical research and production.

Market Share: Approximately 20% in the field of bioprocess solutions (2024, estimate)
Research and Development Ratio: 8% of revenue (2024)
EBIT Margin: 25% (2024)

Sartorius Aktiengesellschaft has a significant competitive advantage in the field of bioprocess solutions, where the company holds an estimated market share of about 20%. This positions Sartorius as one of the leading providers in this segment, supported by continuous investments in research and development.

The research and development ratio of 8% of revenue demonstrates the company's commitment to developing innovative solutions and continuously improving its product range. This innovation capability is a key factor in Sartorius' competitive advantage.

Furthermore, the high EBIT margin of 25% contributes to the financial stability and flexibility of the company, enabling Sartorius to make strategic investments and further strengthen its market position.

Institutional Investor Share: approx. 60% (estimated for 2025)
Insider Trades: No specific data available for 2025

The institutional investor share in Sartorius Aktiengesellschaft traditionally remains at a high percentage, indicating the trust of large institutional investors in the company's long-term growth strategy. These investors typically include pension funds, investment funds, and other major financial institutions.

There is currently no specific information available regarding insider trades in 2025. Such transactions are usually carried out by company management or significant shareholders and can serve as an indicator of their confidence in the company's future development. It is advisable to regularly check the publications of the Federal Financial Supervisory Authority (BaFin) or similar sources to obtain up-to-date information.

Market Share of Sartorius AG: Estimated 10-12% (2025)

Main Competitors and Their Market Shares:

1. Thermo Fisher Scientific: approx. 15-17%
2. Danaher Corporation: approx. 13-15%
3. Merck KGaA: approx. 10-12%
4. Agilent Technologies: approx. 8-10%
5. Bio-Rad Laboratories: approx. 5-7%

Sartorius AG is a significant player in the field of bioprocess solutions and laboratory technology. Sartorius' market share is estimated at around 10-12%, making the company one of the leading providers in this sector. However, the market is highly fragmented and competitive.

Sartorius' moat lies primarily in its specialization in biotechnology and pharmaceuticals, with a strong focus on innovative solutions and technologies. This enables the company to establish itself in a rapidly growing market. Sartorius has gained an advantage through strategic acquisitions and a strong R&D strategy.

Compared to its competitors, Sartorius has a solid, but not insurmountable moat. Thermo Fisher Scientific and Danaher Corporation may have a stronger moat due to their broader product range and larger economies of scale. These companies benefit from extensive distribution networks and a broad customer base, giving them a competitive edge.

Overall, Sartorius has a significant advantage due to its specialization and innovation, but they must continue to invest in research and development to maintain and expand their market position.

Revenue Growth: 10% (2024) EBITDA Margin: 33% (2024) Research and Development Ratio: 8% of revenue (2024)

Sartorius Aktiengesellschaft recorded a revenue growth of 10% in 2024, driven by strong demand in the field of bioprocess solutions. The EBITDA margin of 33% demonstrates solid operational efficiency and the ability to generate high profits from revenues.

The company continuously invests in research and development, with a ratio of 8% of revenue, indicating strong innovation capabilities. These investments are crucial to remain a leader in the competitive market of biotechnology and laboratory equipment.

Sartorius has also expanded its global presence and benefits from the increasing demand for biopharmaceutical products. The strategic focus on growth areas and the continuous expansion of production capacities support long-term growth prospects.

Overall, the solid financial figures and strategic initiatives suggest that Sartorius could be a promising investment for investors interested in long-term growth.

Dividend yield: 0.6% (2025, estimated)
Dividend history: Continuous payout over the last 5 years

Sartorius Aktiengesellschaft has regularly distributed dividends in recent years. The dividend yield is currently around 0.6%, which is relatively low compared to other companies in the industry. This reflects the company's strategy of reinvesting profits more in growth and expansion rather than in high dividend payments.

The reliability of the payout is high, as the company has pursued a stable dividend policy. Dividends have been paid continuously over the past five years, indicating a solid financial foundation and sustainable business development. Analysts expect Sartorius to continue paying dividends in the future, provided there are no significant economic changes.